Geode Capital Management LLC Has $30.11 Million Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Geode Capital Management LLC lifted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 6.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 662,594 shares of the company’s stock after purchasing an additional 38,490 shares during the quarter. Geode Capital Management LLC’s holdings in Janux Therapeutics were worth $30,107,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in Janux Therapeutics by 202.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in shares of Janux Therapeutics in the third quarter worth about $4,943,000. Algert Global LLC bought a new stake in shares of Janux Therapeutics during the 3rd quarter worth about $1,112,000. FMR LLC increased its holdings in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after acquiring an additional 47,075 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Janux Therapeutics in the 2nd quarter valued at approximately $1,676,000. Institutional investors own 75.39% of the company’s stock.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now directly owns 282,054 shares in the company, valued at approximately $15,101,171.16. This represents a 8.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares of the company’s stock, valued at approximately $318,454.88. The trade was a 12.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,801 shares of company stock valued at $3,769,985 in the last 90 days. 29.40% of the stock is currently owned by company insiders.

Janux Therapeutics Stock Down 1.7 %

JANX stock opened at $55.17 on Friday. The business’s 50-day simple moving average is $54.35 and its 200 day simple moving average is $47.35. The company has a market cap of $2.90 billion, a PE ratio of -47.15 and a beta of 3.29. Janux Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s revenue was down 82.6% on a year-over-year basis. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. UBS Group initiated coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price for the company. Stifel Nicolaus upped their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partners lifted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Scotiabank upped their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. Finally, BTIG Research lifted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.